sorafenib drug pathway sorafenib pharmacodynamics pathway 2012-10-04T15:31:17Z PW:0001109 The pathway of sorafenib-target interaction and of the biochemical or physiological responses to drug. Sorafenib is the first multikinase inhibitor approved for the treatment of renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can cause differences in the response of the organism to the drug. pathway vpetri